BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20706715)

  • 1. Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice.
    Lee TY; Kim YH; Lee KS; Kim JK; Lee IH; Yang JM; Sung MH; Park JS; Poo H
    Cancer Immunol Immunother; 2010 Nov; 59(11):1727-37. PubMed ID: 20706715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice.
    Poo H; Pyo HM; Lee TY; Yoon SW; Lee JS; Kim CJ; Sung MH; Lee SH
    Int J Cancer; 2006 Oct; 119(7):1702-9. PubMed ID: 16646080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against human papillomavirus type 16-induced tumors in C57BL/6 mice by mucosal vaccination with Lactococcus lactis NZ9000 expressing E6 oncoprotein.
    Taghinezhad-S S; Mohseni AH; Keyvani H; Razavilar V
    Microb Pathog; 2019 Jan; 126():149-156. PubMed ID: 30391536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7.
    Adachi K; Kawana K; Yokoyama T; Fujii T; Tomio A; Miura S; Tomio K; Kojima S; Oda K; Sewaki T; Yasugi T; Kozuma S; Taketani Y
    Vaccine; 2010 Apr; 28(16):2810-7. PubMed ID: 20170766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
    Komatsu A; Igimi S; Kawana K
    Vaccine; 2018 Jun; 36(24):3423-3426. PubMed ID: 29735324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.
    Yoon SW; Lee TY; Kim SJ; Lee IH; Sung MH; Park JS; Poo H
    Vaccine; 2012 May; 30(22):3286-94. PubMed ID: 22426329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Administration of Poly-Gamma-Glutamic Acid Significantly Enhances the Antitumor Effect of HPV16 E7-Expressing
    Kim E; Yang J; Sung MH; Poo H
    J Microbiol Biotechnol; 2019 Sep; 29(9):1444-1452. PubMed ID: 31387341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with recombinant Lactobacillus casei strains producing K99, K88 fimbrial protein protects mice against enterotoxigenic Escherichia coli.
    Wen LJ; Hou XL; Wang GH; Yu LY; Wei XM; Liu JK; Liu Q; Wei CH
    Vaccine; 2012 May; 30(22):3339-49. PubMed ID: 21856357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
    Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
    Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal Administration of
    Huynh DT; Chathuranga WAG; Chathuranga K; Lee JS; Kim CJ
    J Microbiol Biotechnol; 2024 Mar; 34(3):735-745. PubMed ID: 37915251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
    Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
    Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic Effects of Dendritic Cells Pulsed with a Coden-optimized HPV 16 E6 and E7 Fusion Gene in Vivo and in Vitro.
    Zhou ZX; Li D; Guan SS; Zhao C; Li ZL; Zeng Y
    Asian Pac J Cancer Prev; 2015; 16(9):3843-7. PubMed ID: 25987047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
    Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
    J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects.
    Indrová M; Reinis M; Bubeník J; Jandlová T; Bieblová J; Vonka V; Velek J
    Folia Biol (Praha); 2004; 50(6):184-93. PubMed ID: 15709713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model.
    Zhou X; Qian X; Zhao Q; Lu Y; Xiong M
    Biol Pharm Bull; 2004 Mar; 27(3):303-7. PubMed ID: 14993792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.